Clinical Trial Update: CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating a gene therapy approach combining AAV-delivered follistatin with a VEGF plasmid to counteract age-related muscle declin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcopenia

Drugs mentioned

• AAV-Follistatin gene therapy (AAV-delivered follistatin gene therapy)
• VEGF plasmid gene therapy (VEGF plasmid gene therapy)

Snippet

Sponsor: Unlimited Biotechnology LLC | Conditions: Age-related Muscle Decline | Phase 1, Phase 2 | Status: RECRUITING